INTERNET MULTICENTER THERAPEUTIC TRIALS OF X LINKED ADRENOLEUKODYSTROPHY
INTERNET MULTICENTER THERAPEUTIC TRIALS OF X LINKED ADRENOLEUKODYSTROPHY
批准号:
7420426
负责人:
HUGO W MOSER
金额:
$3.74万
依托单位国家:
美国
项目类别:
财政年份:
2006
资助国家:
美国
项目状态:
已结题
起止时间:
2006-09-01 至 2007-08-31
中文摘要
该子项目是利用NIH/NCRR资助的中心赠款提供的资源的许多研究子项目之一。子项目和研究者(PI)可能从另一个NIH来源获得了主要资金,因此可以在其他CRISP条目中表示。所列机构为中心,不一定是研究者所在机构。Moser博士的研究项目主要涉及X连锁肾上腺脑白质营养不良(X-ALD),并涉及这种疾病的各个方面,从分子生物学到动物模型,临床诊断和治疗方案。我们的实验室已经关注这种疾病超过20年,已经确定了5000多名患者,并被认为是X-ALD研究和治疗的国家和国际资源。MRI和MRS对于X-ALD的诊断以及发病机制的基础研究都是至关重要的,无论是在患者还是在这种疾病的小鼠模型中,此外对于治疗干预的决策及其评估都是绝对必要的。X-ALD导致脱髓鞘和轴突损伤,导致进行性神经功能障碍并最终死亡。由于表型表达的显著和不可预测的变化,它提出了诊断和治疗的挑战。表型的范围从导致完全残疾并常常在10岁时死亡的儿童大脑型到较温和的成人型,在另一个极端,成人型可能与仅中度残疾的存活到80年代相容。不同的表型往往共同出现在同一个家庭和不相关的性质突变或严重程度的生化缺陷。MRI和MRS已被发现是最有效的预测临床过程和治疗的评价。MRI异常常表现出特征性的模式。脑MRI异常先于神经系统症状的发展。我们实验室的研究表明,MRS是神经系统受累的一个更敏感的预测因子。Pouwels等人最近的研究表明,聚焦于胆碱和肌醇峰的定量光谱学有助于确定脱髓鞘是处于活动期还是静止期,这些方法现在正在F.M.卡比中心。您的资源项目2中正在开发的MR光谱技术的进步对该计划至关重要。在临床层面,MRI和MRS对于决定患者是否应该接受骨髓移植至关重要。这种方法在仔细定义的情况下是有效的,但具有高风险,不应提供给不需要它的患者,或太残疾而不能从中受益的患者。最近的进展,包括MRS和磁化转移技术是这一决定的关键。这项由FDA和NIH资助的多中心临床试验支持的研究将于10月1日提交申请,涉及对治疗干预措施的评估。MRI和MRS是这些评估的关键,并将通过与国家医学图书馆的合同得到极大的帮助。在这份合同中,“下一代互联网”将被用来将世界各地的图像传输到F.M.。科比中心,他们将在科比中心进行评估。除了这些面向临床的应用外,项目2还将用于增强对患者X-ALD发病机制的理解。这些发病机制的研究将包括与神经病理学和神经生理学改变的比较,以及BMT和药物治疗效果的检查。除MRS外,本研究还将采用TRD 3中开发的方法进行连通性测试。Mori等人最近的论文中展示了第一个结果,MRM 2002年。
英文摘要
This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Dr Moser's research programs relate mainly to X-Linked Adrenoleukodystrophy (X-ALD) and concern all aspects of this disorder, ranging from molecular biology, to animal models, clinical diagnosis, and therapeutic protocols. Our laboratory has been concerned with this disease for more than twenty years, has identified more than five thousand patients, and is considered a national and international resource for the study and therapy of X-ALD. MRI and MRS are crucial for the diagnosis of X-ALD, and also for basic studies of pathogenesis, both in patients and in a mouse model of this disease, and in addition are absolutely essential to decisions about therapeutic interventions and to their evaluation. X-ALD causes demyelination and axonal damage, which lead to progressive neurological disability and eventually to death. It presents diagnostic and therapeutic challenges because of striking and unpredictable variations in phenotypic expression. The phenotype ranges fr om the chi ldhood cerebral form which leads to total disability and often to death by ten years of age, to milder adult forms, which at the other extreme may be compatible with survival to the eight's decade with only moderate disability. The various phenotypes often co-occur in the same family and do not correlate with the nature of the mutation or the severity of the biochemical deficit. MRI and MRS have been found to be the most valid predictors of clinical course and the evaluation of therapy. The MRI abnormalities often shown characteristic patterns. Brain MRI abnormalities precede the development of neurological symptoms. Studies in our lab have shown that MRS is an even more sensitive predictor of neurological involvement. Recent studies by Pouwels et al. indicate that quantitative spectroscopy with focus on the choline and myoinositol peaks help to determine whether demyelination is in an active or quiescent stage, and these approaches are now being utilized and extended at the F.M. K irby Center. The advances in MR spectroscopy techniques, being developed in Project 2 of your Resource are of critical importance to this program. At the clinical level MRI and MRS are essential for the decision whether a patient should receive a bone marrow transplant. This procedure is effective under carefully defined circumstances, but carries a high risk and should not be offered to patients who do not need it, or are too disabled to benefit from it. Recent advances, including MRS and magnetization transfer techniques are of key importance to this decision. The study supported by the FDA and the Multicenter Clinical Trial for which NIH funding for is requested in our application to be submitted on October 1, involve the evaluation of therapeutic interventions. MRI and MRS are key to these evaluations and will be assisted greatly through the Contract with the National Library of Medicine. In this contract the "next generation internet" will be utilized to transmit images from all parts of the world to the F.M. Kirby Center, where they will be evaluated in the Kirby Center. In addition to these clinically oriented applications, Project 2 will be applied to enhance understanding of the pathogenesis of X-ALD in patients. These studies of pathogenesis will include comparisons with neuropathological and neurophysiological alterations as well as examination of the effects of BMT and pharmacological therapies. In addition to MRS, the present studies will also employ connectivity testing using the methodology developed in TRD3. A first result was shown in the recent paper by Mori et al., MRM 2002.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
X-LINKED ADRENOLEUKODYSTROPHY
-
批准号:7602576
-
项目类别:
-
资助金额:$3.45万
-
财政年份:2007
-
负责人:HUGO W MOSER
-
依托单位:
PLACEBO-CONTROLLED STUDY OF X-ALD DIET THERAPY
-
批准号:7604721
-
项目类别:
-
资助金额:$0.35万
-
财政年份:2006
-
负责人:HUGO W MOSER
-
依托单位:
THERAPEUTIC TRIALS OF X-LINKED ALD: PHASE III; LORENZO*
-
批准号:7061895
-
项目类别:
-
资助金额:$34.81万
-
财政年份:2006
-
负责人:HUGO W MOSER
-
依托单位:
STUDIES IN ADRENOMYELONEUROPATHY
-
批准号:7200729
-
项目类别:
-
资助金额:$1.17万
-
财政年份:2005
-
负责人:HUGO W MOSER
-
依托单位:
INTERNET MULTICENTER THERAPEUTIC TRIALS OF X LINKED ADRENOLEUKODYSTROPHY
-
批准号:7182876
-
项目类别:
-
资助金额:$2.59万
-
财政年份:2005
-
负责人:HUGO W MOSER
-
依托单位:
EFFECT OF GLYCEROL TRIERUCATE ON CLINICAL COURSE OF ADRENOLEUKODYSTROPHY
-
批准号:7378767
-
项目类别:
-
资助金额:$1.48万
-
财政年份:2005
-
负责人:HUGO W MOSER
-
依托单位:
PLACEBO-CONTROLLED STUDY OF X-ALD DIET THERAPY
-
批准号:7378967
-
项目类别:
-
资助金额:$0.25万
-
财政年份:2005
-
负责人:HUGO W MOSER
-
依托单位:
PLACEBO-CONTROLLED STUDY OF X-ALD DIET THERAPY
-
批准号:7378853
-
项目类别:
-
资助金额:$1.97万
-
财政年份:2005
-
负责人:HUGO W MOSER
-
依托单位:
EFFECT OF GLYCERYL TRIERUCATE THERAPY OF ALD
-
批准号:7378950
-
项目类别:
-
资助金额:$0.04万
-
财政年份:2005
-
负责人:HUGO W MOSER
-
依托单位:
EFFECT OF GLYCEROL TRIERUCATE ON CLINICAL COURSE OF ADRENOLEUKODYSTROPHY
-
批准号:7200658
-
项目类别:
-
资助金额:$2.92万
-
财政年份:2005
-
负责人:HUGO W MOSER
-
依托单位:
EFFECT OF GLYCERYL TRIERUCATE THERAPY OF ALD
-
批准号:7200826
-
项目类别:
-
资助金额:$0.15万
-
财政年份:2005
-
负责人:HUGO W MOSER
-
依托单位:
STUDIES IN ADRENOMYELONEUROPATHY
-
批准号:7200838
-
项目类别:
-
资助金额:$0.82万
-
财政年份:2005
-
负责人:HUGO W MOSER
-
依托单位:
INTERNET MULTICENTER THERAPEUTIC TRIALS OF X LINKED ADRENOLEUKODYSTROPHY
-
批准号:6972701
-
项目类别:
-
资助金额:$2.48万
-
财政年份:2004
-
负责人:HUGO W MOSER
-
依托单位:
Studies in Adrenomyeloneuropathy
-
批准号:7044744
-
项目类别:
-
资助金额:$1.82万
-
财政年份:2003
-
负责人:HUGO W MOSER
-
依托单位:
Effect of Docosahexaenoic Acid Therapy in Peroxisomal Disorders
-
批准号:7044564
-
项目类别:
-
资助金额:$0.03万
-
财政年份:2003
-
负责人:HUGO W MOSER
-
依托单位:
Effect of Glyceryl Trierucate Therapy of ALD
-
批准号:7044726
-
项目类别:
-
资助金额:$0.2万
-
财政年份:2003
-
负责人:HUGO W MOSER
-
依托单位:
Effect of Glycerol Trierucate on Clinical Course of Adrenoleukodystrophy
-
批准号:7044576
-
项目类别:
-
资助金额:$1.38万
-
财政年份:2003
-
负责人:HUGO W MOSER
-
依托单位:
Studies in Adrenomyeloneuropathy
-
批准号:7044678
-
项目类别:
-
资助金额:$1.61万
-
财政年份:2003
-
负责人:HUGO W MOSER
-
依托单位:
Multicenter Therapeutic Trials of X-Linked ALD
-
批准号:6662041
-
项目类别:
-
资助金额:$72.0万
-
财政年份:2002
-
负责人:HUGO W MOSER
-
依托单位:
Multicenter Therapeutic Trials of X-Linked ALD
-
批准号:6802403
-
项目类别:
-
资助金额:$80.0万
-
财政年份:2002
-
负责人:HUGO W MOSER
-
依托单位:
国内基金
海外基金
登录
查看更多内容
HIF-1α调控软骨细胞衰老在骨关节炎进展中的作用及机制研究
-
批准号:82371603
-
项目类别:面上项目
-
资助金额:49.00万元
-
批准年份:2023
-
负责人:陈晓
-
依托单位:
间皮细胞衰老在腹膜透析后腹膜适应不良修复和纤维化发病中的作用及机制研究
-
批准号:82370743
-
项目类别:面上项目
-
资助金额:49.00万元
-
批准年份:2023
-
负责人:姜娜
-
依托单位:
衰老抑制脊髓损伤修复的CXCL13依赖性CD8+T细胞通讯机制研究
-
批准号:82371585
-
项目类别:面上项目
-
资助金额:49.00万元
-
批准年份:2023
-
负责人:周鲁明
-
依托单位:
衰老上皮细胞FABP4调控HSDL2致脂肪酸代谢失衡在BPH发病中的机制研究
-
批准号:82370774
-
项目类别:面上项目
-
资助金额:49.00万元
-
批准年份:2023
-
负责人:阮渊
-
依托单位:
LMNA基因R527C纯合突变儿童早老症干细胞功能异常及分子机理研究
-
批准号:32100603
-
项目类别:青年科学基金项目(C类)
-
资助金额:30.0万元
-
批准年份:2021
-
负责人:周焱
-
依托单位:
NRF2/MFN2/ERS信号异常促进ADSCs衰老和肥大型肥胖皮下脂肪组织胰岛素抵抗的机制研究
-
批准号:32000511
-
项目类别:青年科学基金项目
-
资助金额:24.0万元
-
批准年份:2020
-
负责人:方佳
-
依托单位:
SIRT2在灵长类心肌衰老进程中的作用及其机制研究
-
批准号:32000510
-
项目类别:青年科学基金项目
-
资助金额:24.0万元
-
批准年份:2020
-
负责人:范艳玲
-
依托单位:
隐性遗传方式儿童早老症患者SASP-like炎症反应病理特征和分子机制研究
-
批准号:32060157
-
项目类别:地区科学基金项目
-
资助金额:36.0万元
-
批准年份:2020
-
负责人:舒伟
-
依托单位:
c-Fos在皮肤上皮干细胞衰老中的作用研究
-
批准号:32070730
-
项目类别:面上项目
-
资助金额:58.0万元
-
批准年份:2020
-
负责人:张亮
-
依托单位:
SETD8介导H4K20单甲基化修饰对MSCs抗衰老的作用机制
-
批准号:32060156
-
项目类别:地区科学基金项目
-
资助金额:36.0万元
-
批准年份:2020
-
负责人:刘鹏霞
-
依托单位: